Tencent and BGF led a $91m Series A round in T-Therapeutics.

Tencent, a Chinese multinational technology conglomerate and holding company, and BGF, an investment partner for growing companies, led a $91m Series A round in T-Therapeutics, a cutting-edge biotech company. “Our transformative medicines tackle upstream disease-drivers that can have pan-indication impact. We are delighted to have significantly added to our Series A financing, which we see as a strong validation of both our technology and our progress to date. I would like to thank Tencent and BGF for their belief in our potential, as well as all our existing investors for their continued support,” Theodora Harold, T-Therapeutics Chief Executive Officer.